Ascendis Pharma A (ASND) Short term Debt (2021 - 2025)

Ascendis Pharma A (ASND) has 5 years of Short term Debt data on file, last reported at $446.7 million in Q4 2025.

• For the quarter ending Q4 2025, Short term Debt fell 8.76% year-over-year to $446.7 million; the trailing twelve-month figure through Dec 2025 stood at $446.7 million (down 8.76% YoY), and the FY2025 full-year result was $446.7 million, down 9.92% from the prior year.
• Short term Debt slipped to $446.7 million in Q4 2025, from $489.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $489.6 million in Q4 2024 to a low of $8.0 million in Q4 2021.
• A 5-year average of $278.8 million and a median of $438.0 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 3591.46% in 2023 and declined 8.76% in 2025, its largest moves.
• Tracing ASND's Short term Debt over 5 years: stood at $8.0 million in 2021, then soared by 48.28% to $11.9 million in 2022, then jumped by 3591.46% to $438.0 million in 2023, then advanced by 11.79% to $489.6 million in 2024, then dropped by 8.76% to $446.7 million in 2025.
• Business Quant data shows ASND's Short term Debt at $446.7 million in Q4 2025, $489.6 million in Q4 2024, and $438.0 million in Q4 2023.